<?xml version="1.0" encoding="UTF-8"?>
<ref id="B27-vaccines-07-00074">
 <label>27.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Simek</surname>
    <given-names>M.D.</given-names>
   </name>
   <name>
    <surname>Rida</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Priddy</surname>
    <given-names>F.H.</given-names>
   </name>
   <name>
    <surname>Pung</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Carrow</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Laufer</surname>
    <given-names>D.S.</given-names>
   </name>
   <name>
    <surname>Lehrman</surname>
    <given-names>J.K.</given-names>
   </name>
   <name>
    <surname>Boaz</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Tarragona-Fiol</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Miiro</surname>
    <given-names>G.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm</article-title>
  <source>J. Virol.</source>
  <year>2009</year>
  <volume>83</volume>
  <fpage>7337</fpage>
  <lpage>7348</lpage>
  <pub-id pub-id-type="doi">10.1128/JVI.00110-09</pub-id>
  <pub-id pub-id-type="pmid">19439467</pub-id>
 </element-citation>
</ref>
